Results 31 to 40 of about 4,782 (272)

Airway mucus and 129Xe MRI ventilation after single inhaler triple therapy in asthma

ERJ Open Research
Background In asthma, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) was previously demonstrated to improve forced expiratory volume in 1 s (FEV1) and asthma control, but the mechanism by which this occurs, especially at the level of the small ...
Ali Mozaffaripour, Sam Tcherner, Eveline Durom, Harkiran K. Kooner, Marrissa J. McIntosh, Malcolm Sherwood, Narinder Paul, Hana Serajeddini, Anurag Bhalla, Cory Yamashita, Grace Parraga   +10 more
doaj   +4 more sources

Triple Therapy for COPD: Historical Perspective and Current Controversies

Barcelona Respiratory Network Reviews, 2023
The use of a combination of three inhaled drugs has recently been established as the first choice for some patients in the algorithm for the treatment of chronic obstructive pulmonary disease. In this review, we aim to give an overview of the development
Jose L. López-Campos
doaj   +1 more source

Single-Inhaler Triple versus Dual Therapy in Patients with COPD [PDF]

New England Journal of Medicine, 2018
In the randomized Informing the Pathway of COPD Treatment (IMPACT) trial involving more than 10,000 patients with chronic obstructive pulmonary disease (COPD), Lipson and colleagues (May 3 issue) compared a once- daily combination of f luticasone furoate (an inhaled glucocorticoid), umeclidinium (a long- acting muscarinic antagonist [LAMA]), and ...
Wedzicha, JA, Banerji, D, Kostikas, K
openaire   +7 more sources

Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study)

BMJ Open Respiratory Research, 2023
Introduction From 2018 single inhaler triple therapy (SITT) became available in France to treat moderate-to-severe chronic obstructive pulmonary disease (COPD).
Gaëtan Deslee, Andrew Maguire, Gabriel Thabut, Caroline Fabry-Vendrand, Nolwenn Poccardi, Caroline Eteve Pitsaer, Adrien Coriat, Charlotte Renaudat, Thomas Pinto   +8 more
doaj   +1 more source

Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT

Annals of the American Thoracic Society, 2021
Abstract Rationale In the IMPACT (Informing the Pathway of COPD Treatment) trial, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy reduced exacerbation risk versus FF/VI and UMEC/VI and mortality risk versus UMEC/VI.
Mark T. Dransfield, Courtney Crim, Gerard J. Criner, Nicola C. Day, David M. G. Halpin, MeiLan K. Han, C. Elaine Jones, Sally Kilbride, David LaFon, David A. Lipson, David A. Lomas, Neil Martin, Fernando J. Martinez, Dave Singh, Robert A. Wise, Peter Lange   +15 more
openaire   +4 more sources

Evaluating Patient Preferences of Maintenance Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Discrete Choice Experiment in the UK, USA and Germany. [PDF]

, 2020
Introduction: With increasing availability of different treatments for chronic obstructive pulmonary disease (COPD), we sought to understand patient preferences for COPD treatment in the UK, USA, and Germany using a discrete choice experiment (DCE ...
Doll, HA, Gunsoy, NB, Ismaila, AS, Janssen, EM, Jones, PW, Lewis, HB, Llewellyn, S, Schroeder, M   +7 more
core   +1 more source

Triple Therapy of Fluticasone Furoate, Umeclidinium, Vilanterol- A Compelling Choice in Severe Chronic Obstructive Pulmonary Disease [PDF]

Journal of Clinical and Diagnostic Research, 2021
Trelegy Ellipta (GlaxoSmithKlineTM) is the first single inhaler triple combination therapy comprising of umeclidinium, vilanterol and fluticasone approved by the United States Food and Drug Administration (US FDA) for patients with severe COPD in 2019.
B Jagan Nathan, Melina I Sahay, AK Gautham, DK Sriram, Melvin George   +4 more
doaj   +1 more source

Risk of Exacerbation and Pneumonia with Single Inhaler Triple versus Dual Therapie in IMPACT [PDF]

Pneumologie, 2018
Background: To determine overall benefit-risk, we examined the effect of single inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI and FF/VI on the composite outcome of acute exacerbation of COPD or pneumonia in the IMPACT study, a 52-week, randomized, multicentre study in patients with symptomatic COPD and prior ...
Mark Dransfield, Courtney Crim, Gerard Criner, David Halpin, Meilan Han, C. Elaine Jones, Sally Kilbride, Peter Lange, David Lipson, David Lomas, Fernando Martinez, David Singh, Robert Wise   +12 more
openaire   +1 more source

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: A randomized non-inferiority study [PDF]

, 2018
Background: Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obstructive ...
Birk, Ruby, Brealey, Noushin, Bremner, Peter R, Ismaila, Afisi S, Lipson, David A, Zhu, Chang-Qing   +5 more
core   +2 more sources

Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease [PDF]

, 2010
Background Combination therapy (inhaled corticosteroids and long-acting beta(2)-agonists) and tiotropium are both used in the treatment of chronic obstructive pulmonary disease (COPD).
Appleton, Appleton, Appleton, Barr, Bateman, Calverley, Effing, Jones, Karner, Keene, Kesten, Lacasse, Nannini, Nannini, Nannini, Singh, Singh, Suissa, Suissa, Tashkin, Yang   +20 more
core   +1 more source